<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-16T00:56:30Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/7mmz9p83bn.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/7mmz9p83bn.1</identifier>
                <datestamp>2023-02-23T15:43:38Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>Kulenovic, Adnan</dc:creator>
    <dc:title>Minimization of Drug Interactions in Polypharmacy Treatments of Diabetes Mellitus Type 2 with Cardiovascular Comorbidities by Using the Decision Support Tool PM-TOM</dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>Study: Minimization of Drug Interactions in Polypharmacy Treatments of Diabetes Mellitus Type 2 with Cardiovascular Comorbidities by Using the Decision Support Tool PM-TOM.

The results of this study demonstrate that DDIs in combined polypharmacy treatments of DMT2 with its cardiovascular comorbidities can be significantly reduced by using decision support tools, like PM-TOM, while observing medical guidelines and specific patient conditions. Furthermore, the study method can be applied to any other set of DMT2 comorbidities and also to any other multi-disease. 
The groups of analytical treatment cases correspond to possible development stages of the considered conditions; however, they do not suggest the only ways to combine drug classes. Still, the case groups and cases analyzed in the study cover a wide set of possible treatment cases, sufficient to draw the above conclusions. This study can be used as a background for specific studies of combined polypharmacy treatments and further upgrades of the medical guidelines. 

</dc:description>
    <dc:subject>Drug Receptor Interactions</dc:subject>
    <dc:subject>Drug Adverse Reactions</dc:subject>
    <dc:subject>Drug Treatment of Diabetes</dc:subject>
    <dc:contributor id="https://orcid.org/0000-0003-1304-9201">Kulenovic, Azra</dc:contributor>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/7mmz9p83bn.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/7mmz9p83bn.1</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/7mmz9p83bn</dc:relation>
    <dc:date>2023-02-23T15:43:38Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
